Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Replicate Bioscience Inc. maintains a patent portfolio focused on the Chemistry & Materials technology area, currently navigating 3 pending office actions. These actions are distributed across 3 distinct examiners, suggesting a lack of examiner overlap in their current prosecution efforts. While the workload is spread among multiple individuals, it is contained within 2 distinct art units, indicating a degree of thematic consistency in how the USPTO categorizes their innovations.
KIM, SUN U is identified as the busiest examiner for the company, though this individual is only responsible for 1 pending office action. This distribution highlights that no single examiner holds a majority of the active cases, requiring the company to manage multiple examiner relationships simultaneously. The presence of 2 distinct art units suggests that while the technology is specialized, it touches upon different examination subgroups within the broader chemistry field. With several examiners involved, the company must adapt its arguments to different perspectives even within a relatively small set of active cases.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, SUN U | 1 | 78.2% | +11.5% |
| CHESTNUT, BARRY A | 1 | 73.5% | +6.4% |
| FOLEY, SHANON A | 1 | 73.3% | +18.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007036 | MODIFIED CHIKUNGUNYA VIRUSES AND SINDBIS VIRUSES AND USES THEREOF | FOLEY, SHANON A | 34d |
| 18713901 | COMPOSITIONS AND METHODS FOR INDUCING ESR1, PI3K, HER2, AND HER3 IMMUNE RESPONSES | CHESTNUT, BARRY A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007036 | MODIFIED CHIKUNGUNYA VIRUSES AND SINDBIS VIRUSES AND USES THEREOF | FOLEY, SHANON A | 34d |
| 18731901 | SYSTEM AND METHOD FOR CARDIOPULMONARY BYPASS USING HYPOBARIC OXYGENATION | KIM, SUN U | — |
| Art Unit | Apps |
|---|---|
| 1777 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18731901 | SYSTEM AND METHOD FOR CARDIOPULMONARY BYPASS USING HYPOBARIC OXYGENATION | KIM, SUN U | 1777 | §102§103DP | Non-Final OA | — | Pending | Jun 03, 2024 |
| 18713901 | COMPOSITIONS AND METHODS FOR INDUCING ESR1, PI3K, HER2, AND HER3 IMMUNE RESPONSES | CHESTNUT, BARRY A | — | §101DP | Non-Final OA | — | Pending | May 28, 2024 |
| 18007036 | MODIFIED CHIKUNGUNYA VIRUSES AND SINDBIS VIRUSES AND USES THEREOF | FOLEY, SHANON A | 1671 | §102§103§112 | Non-Final OA | 34d | Pending | Jan 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial